Omer, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (Nasdaq: ODYS), a leading provider of visual based predictive maintenance (PdM) and condition-based monitoring (CBM) solutions, today announced it will participate in the 15th Annual ROTH London Conference taking place June 25–26, 2025, in London, U.K. Einav Brenner, Chief Financial Officer, will be available for one-on-one investor meetings on site both days. To schedule a meeting, please contact your ROTH representative. About the ROTH Londo ...

Core Viewpoint - Intensity Therapeutics, Inc. has announced a public offering of 6,675,000 shares at a price of $0.30 per share, aiming to raise approximately $2,002,500 before expenses, with a closing date expected on June 13, 2025 [1][2] Group 1: Offering Details - The public offering consists of 6,675,000 shares priced at $0.30 each, generating gross proceeds of $2,002,500 [1] - The underwriters have a 45-day option to purchase an additional 1,001,250 shares to cover over-allotments [1] - The offering will close on June 13, 2025, pending customary closing conditions [1] Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for patient enrollment and data readout in the INVINCIBLE-4 Study, treatment of patients in the INVINCIBLE-3 Study, and for general corporate purposes [2] Group 3: Company Overview - Intensity Therapeutics is a late-stage clinical biotechnology company focused on developing immune-based intratumoral cancer therapies [5] - The investigational drug INT230-6 has shown potential in killing tumors and eliciting immune responses, with over 200 patients enrolled in clinical trials [5] - The company has completed two clinical studies and initiated a Phase 3 trial in soft tissue sarcoma and a Phase 2 study for presurgical triple-negative breast cancer [5]

Core Viewpoint - Intensity Therapeutics, Inc. plans to conduct an underwritten public offering of its common stock to fund clinical trials and general corporate purposes [1][2]. Company Overview - Intensity Therapeutics is a late-stage clinical biotechnology company focused on developing immune-based intratumoral cancer therapies that aim to kill tumors and enhance immune system recognition of cancers [1][5]. - The company has developed a novel drug, INT230-6, which has shown the ability to kill tumors and elicit an adaptive immune response shortly after injection, potentially transforming the treatment of various cancers [5]. Clinical Trials and Studies - Intensity has completed two clinical studies involving over 200 patients, including a Phase 1/2 dose escalation study in metastatic cancers and a Phase 2 randomized control trial in locally advanced breast cancer [5]. - The company is currently conducting a Phase 3 trial in soft tissue sarcoma (INVINCIBLE-3 Study) and a Phase 2 study in collaboration with The Swiss Group for Clinical Cancer Research (INVINCIBLE-4 Study) [5]. Use of Proceeds - The net proceeds from the public offering will be allocated to patient enrollment and data readout for the INVINCIBLE-4 Study, treatment of patients in the INVINCIBLE-3 Study, and for working capital and general corporate purposes [2]. Offering Details - The securities will be offered under a shelf registration statement filed with the SEC, and a preliminary prospectus supplement will be available for interested parties [3].

BrightSpring Health Services (BTSG) FY 2025 Conference June 11, 2025 02:40 PM ET Speaker0 Wanted to start, you just joined as CFO. You've been with the company a long time, but just as you get to know the investor community, just wanted to give you a chance to talk about your background and what you bring to the CFO seat that's new and helps the strategy of the company going forward. Speaker1 Sure. Thank you. I've been with the company for over eight and a half years, have been a part of everything that we' ...

Novavax (NVAX) FY Conference June 11, 2025 02:00 PM ET Speaker0 Are we ready to go? Are we live? Oh, hello, everyone. Speaker1 Hi, I'm John Jacobs, CEO of Novavax, and I'm joined here today by Jim Kelly, our CFO, and Doctor. Roxandra Draghia, who heads up our R and D. I want to thank everyone who's here today to join us and listening in to our presentation at the Goldman Sachs forty sixth Annual Global Healthcare Conference. Today's 06/11/2025. I'll advance the slide to our cautionary note regarding forward ...

Core Insights - Unisys Corporation (UIS) is focusing on Device Subscriptions Service (DSS) as a growth driver within its Digital Workplace Solutions (DWS) segment, aligning innovations with client needs such as cost optimization and security [1][9] - The company has established a solid pipeline of DSS opportunities, leading to new client investments, including contracts for 380,000 devices with a global tech company and 21,000 devices with a biotech client [2][9] - Unisys has added technology partners Easy Vista and Freshworks to enhance its DWS ecosystem, expecting an increase in DSS signings in the latter half of the year [3][9] Competitive Landscape - Unisys is competing in the device-as-a-service (DaaS) market against major players like HP Inc. and Dell Technologies, both of which have established subscription-based hardware platforms [4] - HP's DaaS model offers bundled solutions with analytics-driven fleet management, targeting large enterprises for operational efficiency [5] - Dell's APEX and ProSupport services provide robust endpoint security and automation, emphasizing flexibility and integration similar to Unisys' approach [6][7] Financial Performance - Unisys shares have increased by 22.4% over the past three months, outperforming the industry growth of 5% [8] - The company's current valuation is attractive, with a forward 12-month price-to-earnings (P/E) ratio of 5.23X, indicating a discount compared to industry peers [11] - The Zacks Consensus Estimate predicts a year-over-year earnings increase of 28.9% for 2025 and 120.7% for 2026, with stable earnings estimates over the past month [13]

Core Insights - BrightSpring Health Services, Inc. (BTSG) is experiencing significant growth in its Home Health Care segment, driven by the expanding global home healthcare market, which is projected to grow at a CAGR of 10.21% from 2025 to 2030 [1] Company Performance - The Home Health Care segment generated $178 million in sales in Q1 2025, reflecting a 21% year-over-year increase, supported by strong operational execution and expanding Medicare Advantage contracts [2][8] - The average daily census across home health and hospice increased to over 30,000, a 12% rise from the previous year, indicating robust demand for services [3] - Approximately 90% patient satisfaction was reported, with over 80% of branches rated 4 stars or higher, and a declining 60-day hospitalization rate [2][3] Strategic Initiatives - BrightSpring is advancing its Homebase Primary Care model to provide physician-led services in cost-effective, in-home settings, and is targeting scalable growth to over 100,000 patients through value-based models like ACOs and SNPs [3] Competitive Landscape - Cardinal Health's at-Home Solutions is expanding its reach in the home healthcare market, serving over 5 million patients in fiscal 2024 and investing in automated distribution centers to enhance capabilities [4] - Addus HomeCare Corporation's home healthcare segment is experiencing modest growth, focusing on selective M&A and leveraging technology for operational synergies [5] Market Valuation - BTSG shares have increased by 98.8% over the past year, significantly outperforming the industry, which saw an 18.9% decline, while the S&P 500 composite grew by 11.8% [6] - The company trades at a forward price-to-earnings ratio of 20.32, above the industry average of 14.25 [9] Earnings Estimates - The Zacks Consensus Estimate for BTSG's earnings has been rising over the past 60 days, with current estimates for Q2 2025 at $0.22 and for the current year at $1.02 [10][11]

Core Insights - SuperCom's subsidiary, Leaders in Community Alternatives (LCA), has secured a contract in Northern California valued at up to $2.5 million over five years to provide reentry services for justice-involved individuals, expected to generate approximately $500,000 in annual recurring revenue [1][2][3] Group 1: Contract Details - The contract includes a three-year initial term with two optional one-year extensions, reinforcing LCA's established presence in the region [1][2] - LCA will offer community-based reentry programming, including case management, employment support, and behavioral health referrals, aimed at reducing recidivism and promoting community safety [3][4] Group 2: Company Reputation and Strategy - The contract win highlights SuperCom's reputation as a trusted provider of public safety solutions, particularly in California, and reflects the company's competitive advantage through customized offerings [4][5] - SuperCom has recently secured over 20 direct contracts and expanded into 10 new states, indicating a strong growth trajectory and long-term value potential in the public safety sector [5] Group 3: Company Background - SuperCom has been a global provider of secure solutions since 1988, focusing on e-Government, IoT, and Cybersecurity sectors, with a comprehensive suite of advanced safety and identification solutions [6] - LCA has over 33 years of experience in providing community-based services and electronic monitoring programs, utilizing evidence-based practices to address recidivism [7]

Core Insights - Laird Superfood has launched a new product, the Protein Instant Latte, which combines convenience with nutritional benefits, featuring 10 grams of protein per serving from a blend of plant-based sources [1][2][3] - The product is designed to meet the growing consumer demand for protein-rich foods and offers additional benefits from functional mushroom extracts [2][3] - The Protein Instant Latte is priced at approximately $19 for a bag containing 6 servings, making it a cost-effective alternative to traditional coffee shop lattes [2][4] Company Overview - Laird Superfood, founded in 2015 by surfer Laird Hamilton, focuses on minimally processed superfood products aimed at enhancing energy and overall well-being [5] - The brand has expanded its product line from superfood creamers to include instant lattes, coffees, bars, and prebiotic greens, all made with simple ingredients [5] - The company emphasizes a commitment to clean, real food ingredients that support active lifestyles [5]

Core Insights - Florida Oncology and Hematology has relocated its Goodlette clinic in Naples to a larger facility to enhance cancer care services for the local community [1][3] - The new clinic features additional private exam rooms, an infusion room, in-house lab and pathology services, and an onsite specialty pharmacy [2][5] - The practice is part of the American Oncology Network, which supports community-based oncology practices and provides additional patient care services [4][7] Company Overview - Florida Oncology and Hematology specializes in the diagnosis and treatment of cancer and blood disorders, serving patients in Cape Coral, Clearwater, Fort Myers, and Naples [8] - The practice emphasizes personalized care and treatment plans tailored to individual patient needs, ensuring affordable and high-quality services [3][8] - American Oncology Network, founded in 2018, is a rapidly expanding network with over 290 providers across 21 states, focusing on value-based care and health equity [6][7]